The difficulties of supplying new technologies into highly regulated markets: the case of tissue engineering

W Phillips, T E Johnsen, Nigel Caldwell, Julian B Chaudhuri

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This study provides an insight into the difficulties companies encounter in transposing basic science into commercially viable healthcare technologies, focusing on the issue of establishing a dominant supply model within a highly regulated market. The core issue is how to scale-up customised scientific processes into products able to supply wider and possibly mass markets. In tracing the development of approaches to scaling-up, the paper highlights the influence regulatory regimes have on high technology regulated products and services. The paper details the implications of two contrasting supply initiatives towards operationalising tissue engineering, based on differences in regulatory regimes between Europe and the USA.
Original languageEnglish
Pages (from-to)213-226
Number of pages14
JournalTechnology Analysis and Strategic Management
Volume23
Issue number3
DOIs
Publication statusPublished - 2011

Fingerprint

Regulatory regime
Scaling
Healthcare
High technology

Keywords

  • new technologies
  • regulation
  • supply

Cite this

The difficulties of supplying new technologies into highly regulated markets: the case of tissue engineering. / Phillips, W; Johnsen, T E; Caldwell, Nigel; Chaudhuri, Julian B.

In: Technology Analysis and Strategic Management, Vol. 23, No. 3, 2011, p. 213-226.

Research output: Contribution to journalArticle

Phillips, W ; Johnsen, T E ; Caldwell, Nigel ; Chaudhuri, Julian B. / The difficulties of supplying new technologies into highly regulated markets: the case of tissue engineering. In: Technology Analysis and Strategic Management. 2011 ; Vol. 23, No. 3. pp. 213-226.
@article{19cfa1d6c17243a3a08fc9cabfbef650,
title = "The difficulties of supplying new technologies into highly regulated markets: the case of tissue engineering",
abstract = "This study provides an insight into the difficulties companies encounter in transposing basic science into commercially viable healthcare technologies, focusing on the issue of establishing a dominant supply model within a highly regulated market. The core issue is how to scale-up customised scientific processes into products able to supply wider and possibly mass markets. In tracing the development of approaches to scaling-up, the paper highlights the influence regulatory regimes have on high technology regulated products and services. The paper details the implications of two contrasting supply initiatives towards operationalising tissue engineering, based on differences in regulatory regimes between Europe and the USA.",
keywords = "new technologies, regulation, supply",
author = "W Phillips and Johnsen, {T E} and Nigel Caldwell and Chaudhuri, {Julian B}",
year = "2011",
doi = "10.1080/09537325.2011.550391",
language = "English",
volume = "23",
pages = "213--226",
journal = "Technology Analysis and Strategic Management",
issn = "0953-7325",
publisher = "Routledge",
number = "3",

}

TY - JOUR

T1 - The difficulties of supplying new technologies into highly regulated markets: the case of tissue engineering

AU - Phillips, W

AU - Johnsen, T E

AU - Caldwell, Nigel

AU - Chaudhuri, Julian B

PY - 2011

Y1 - 2011

N2 - This study provides an insight into the difficulties companies encounter in transposing basic science into commercially viable healthcare technologies, focusing on the issue of establishing a dominant supply model within a highly regulated market. The core issue is how to scale-up customised scientific processes into products able to supply wider and possibly mass markets. In tracing the development of approaches to scaling-up, the paper highlights the influence regulatory regimes have on high technology regulated products and services. The paper details the implications of two contrasting supply initiatives towards operationalising tissue engineering, based on differences in regulatory regimes between Europe and the USA.

AB - This study provides an insight into the difficulties companies encounter in transposing basic science into commercially viable healthcare technologies, focusing on the issue of establishing a dominant supply model within a highly regulated market. The core issue is how to scale-up customised scientific processes into products able to supply wider and possibly mass markets. In tracing the development of approaches to scaling-up, the paper highlights the influence regulatory regimes have on high technology regulated products and services. The paper details the implications of two contrasting supply initiatives towards operationalising tissue engineering, based on differences in regulatory regimes between Europe and the USA.

KW - new technologies

KW - regulation

KW - supply

UR - http://www.scopus.com/inward/record.url?scp=79951819838&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1080/09537325.2011.550391

U2 - 10.1080/09537325.2011.550391

DO - 10.1080/09537325.2011.550391

M3 - Article

VL - 23

SP - 213

EP - 226

JO - Technology Analysis and Strategic Management

JF - Technology Analysis and Strategic Management

SN - 0953-7325

IS - 3

ER -